Rakesh Kumar, PhD, is Founder and CEO of the Breast Cancer in Young Women Foundation, Denver; International Endowed Chair Professor at Swami Rama Himalayan University, India; Visiting Professor at Medanta Cancer Institute, India; Adjunct Professor at Rutgers NJ Medical School, Newark; and Visiting Professor at VCU Medical Center, Richmond, USA. Over a 40-year career, he has contributed to breast cancer research while serving as faculty, Distinguished Professor, Endowed Chair, Dept Vice-chair & Chair at leading US institutions, i.e., Memorial Sloan Kettering Cancer Center & MD Anderson Cancer Center, and as Govt of India National Chair for Cancer Research & Distinguished Professor. He has authored +325 papers & reviews, edited 10 books or volumes, given +300 invited lectures, served on +21 editorial boards and +100 peer panels (i.e., NIH, DoD, VA), mentored 67 trainees, globally ranked < 0.5% in oncology & carcinogenesis over 5 years, received many awards, and had work featured on the covers of 18 journals and two MDACC reports.

Samantha L. Heller, PhD, MD, FSBI, is Professor and Vice Chair of Academic Affairs in the Department of Radiology, New York University Grossman School of Medicine, New York, USA. Prior to this, she served as Division Head of Breast Imaging at NYU. Before joining NYU, she worked as a breast radiologist in the United Kingdom at St George''s Hospital and in the South-West London Screening Service. Dr. Heller serves on the Editorial Board for RadioGraphics and is an Associate Editor for the Science of Screening Section of the Journal of Breast Imaging. She has chaired the Provider and Healthcare Systems Work Group for the CDC Advisory Committee on Breast Cancer in Young Women and is the Society of Breast Imaging lead for the American Society of Breast Surgeons-Society of Breast Imaging Benign Breast Disease Consensus Pathways Guidelines. Ellen Warner, MD, MSc, FRCPC, FACP, is Consulting Staff in the Division of Medical Oncology, Sunnybrook Health Sciences Centre; Senior Scientist Emerita at Sunnybrook Research Institute; and Professor of Medicine Emerita at the University of Toronto, Canada.

A leading Toronto medical oncologist, she is dedicated to the care and research of women with breast cancer and those at high risk. After the discovery of BRCA1/2, she founded Toronto''s first genetic testing program for breast cancer patients with strong cancer family histories. Recognizing mammography''s limits in young mutation carriers, she led a landmark MRI screening trial published in JCO and JAMA, showing that MRI detected 90% of early-stage cancers and establishing annual MRI plus mammography for women with ≥20% lifetime risk. Her work led to the establishment of Ontario''s High-Risk Breast Screening Program. In 2008, she co-founded PYNK: Breast Cancer Program for Young Women and helped lead the RUBY EOBC initiative. She retired from clinical practice in 2025 and remains active in research, teaching, and mentorship. Luis Costa, MD, PhD, is Chair of the Oncology Department at Hospital de Santa Maria, Medical Director of the Clinical Research Center of the Lisbon Academic Medical Center, Professor of Medicine at the University of Lisbon, and Translational Oncology Research Leader at the Gulbenkian Institute for Molecular Medicine in Lisbon. An internationally recognized medical oncologist and researcher, he specializes in metastatic cancer, particularly bone metastases and breast cancer.

He pioneered the clinical use of biochemical markers of bone turnover to monitor treatment response and prognosis in metastatic bone disease, helping redefine skeletal-related events and contributing to the development of bisphosphonates and RANK-ligand inhibitors. His work also advances research on therapeutic resistance, triple-negative disease, and resistance to CDK4/6 & HER2-targeted therapies. Author of 200+ publications, he leads phase I-III trials and serves in major national & international oncology roles. His work also advances research on therapeutic resistance, triple-negative disease, and resistance to CDK4/6 & HER2-targeted therapies. Author of 200+ publications he leads phase I-III trials and serves in major national & international oncology roles.